LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR

The present invention relates to novel lipidated peptide inhibitors of the interleukin- 23 receptor (IL-23R) or pharmaceutically acceptable salts, solvates and/or other forms thereof., corresponding pharmaceutical compositions, methods and/or uses of the IL-23R inhibitors for treatment of autoimmune...

Full description

Saved in:
Bibliographic Details
Main Authors HENDRICK, Charles, ROSOLIA, Federica, BRANCA, Danila, SUN, Chengzao, SOMANI, Sandeep, LOLLOBRIGIDA, Martina, FREDERICK, Brian, RIEXINGER, Douglas, BIANCHI, Elisabetta, NEELAMKAVIL, Santhosh, BARROS, Stephanie, PATCH, Raymond, COSTANTE, Roberto, DANIEL, James, DEL RIZZO, Sonia, TRAN, Tran Trung, ZHANG, Jing, BHANDARI, Ashok
Format Patent
LanguageEnglish
Published 29.02.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to novel lipidated peptide inhibitors of the interleukin- 23 receptor (IL-23R) or pharmaceutically acceptable salts, solvates and/or other forms thereof., corresponding pharmaceutical compositions, methods and/or uses of the IL-23R inhibitors for treatment of autoimmune inflammation diseases and/or related disorders. Included are various, highly-customizable peptide sequences to be tailored to treat a broad range of ailments.
Bibliography:Application Number: AU20220311814